Aripiprazole is classified as an atypical antipsychotic [1]. It is also described as a dopamine-serotonin system stabilizer [2].
What other drugs are in the same class as aripiprazole?
Aripiprazole belongs to the class of atypical antipsychotics, which also includes drugs such as risperidone, olanzapine, quetiapine, ziprasidone, and paliperidone [3]. These medications are distinguished from typical antipsychotics by their lower incidence of extrapyramidal side effects and their efficacy in treating both positive and negative symptoms of schizophrenia [4].
How does aripiprazole work?
Aripiprazole functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors [2]. This unique mechanism of action is believed to modulate dopaminergic and serotonergic neurotransmission, helping to stabilize the dopamine system in the brain, which is implicated in various psychiatric conditions [5].
When did aripiprazole patents expire?
The original patent for aripiprazole, which was developed by Otsuka Pharmaceutical, expired in October 2014 in the United States [6]. This expiry opened the door for generic versions of the drug to enter the market [7].
Who are the main competitors for aripiprazole?
Following the patent expiry of the branded drug Abilify, numerous pharmaceutical companies have introduced generic versions of aripiprazole. Key players in the generic market include Bristol-Myers Squibb, who partnered with Otsuka, and other generic manufacturers producing their own versions of the medication [8]. The market for atypical antipsychotics is competitive, with other drugs in the same class also widely prescribed [3].